Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Post-Market Trading 11-26 18:46:06 EST

0.8000

-0.0169

-2.07%

盘后0.7985

-0.0015-0.19%

18:09 EST

High0.8309	Low0.7709	Vol376.33K
Open0.8111	D1 Closing0.8169	Amplitude7.34%
Mkt Cap54.94M	Tradable Cap30.96M	Total Shares68.67M
T/O300.72K	T/O Rate0.97%	Tradable Shares38.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":0.8,"timestamp":1732654800000,"preClose":0.8169,"halted":0,"volume":376325,"hourTrading":{"tag":"盘后","latestPrice":0.7985,"preClose":0.8,"latestTime":"18:09 EST","volume":150,"amount":119.765496,"timestamp":1732662581955},"delay":0,"floatShares":38706102,"shares":68673612,"eps":-1.649956,"marketStatus":"Post-Market Trading","change":-0.0169,"latestTime":"11-26 18:46:06 EST","open":0.8111,"high":0.8309,"low":0.7709,"amount":300717.4313525,"amplitude":0.073448,"askPrice":0.8408,"askSize":721,"bidPrice":0.7302,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.649956,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732669200000},"marketStatusCode":4,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":0.8169,"preHourTrading":{"tag":"盘前","latestPrice":0.85,"preClose":0.8169,"latestTime":"09:24 EST","volume":1261,"amount":1065.5365513,"timestamp":1732631072449},"postHourTrading":{"tag":"盘后","latestPrice":0.7985,"preClose":0.8,"latestTime":"18:09 EST","volume":150,"amount":119.765496,"timestamp":1732662581955},"volumeRatio":1.059118,"impliedVol":0.4588,"impliedVolPercentile":0.1383},"requestUrl":"/m/hq/s/VOR","defaultTab":"news","newsList":[{"id":"2486203207","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486203207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486203207?lang=en_us&edition=fundamental","pubTime":"2024-11-25 14:00","pubTimestamp":1732514438,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vor Biopharma (VOR – Research Report), Recursion P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-recursion-pharmaceuticals-rxrx-and-an2-therapeutics-inc-antx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-recursion-pharmaceuticals-rxrx-and-an2-therapeutics-inc-antx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4539","VOR","BK4137","ANTX","BK4007","HCSG","RXRX","BK4139"],"gpt_icon":0},{"id":"2482257412","title":"Vor Biopharma’s Trem-cel Therapy Shows Promise with Positive Patient Dosing and Upcoming Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2482257412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482257412?lang=en_us&edition=fundamental","pubTime":"2024-11-11 13:25","pubTimestamp":1731302752,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Silvan Tuerkcan has reiterated their bullish stance on VOR stock, giving a Buy rating on November 8. Silvan Tuerkcan’s ratin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vor-biopharmas-trem-cel-therapy-shows-promise-with-positive-patient-dosing-and-upcoming-data-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vor-biopharmas-trem-cel-therapy-shows-promise-with-positive-patient-dosing-and-upcoming-data-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2481554175","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR) and Sight Sciences (SGHT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481554175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481554175?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:50","pubTimestamp":1731066647,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vor Biopharma (VOR – Research Report) and Sight Sciences (SGHT – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-and-sight-sciences-sght?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-and-sight-sciences-sght?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","VOR","BK4082","BK4139","HCSG","SGHT","BK4539"],"gpt_icon":0},{"id":"2481175539","title":"Vor Bio price target lowered to $14 from $22 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2481175539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481175539?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:50","pubTimestamp":1731066620,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Vor Bio (VOR) to $14 from $22 and keeps an Outperform rating on the shares. The firm said Vor announced 3Q...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-price-target-lowered-to-14-from-22-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-price-target-lowered-to-14-from-22-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2481120724","title":"Vor Biopharma Price Target Maintained With a $17.50/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481120724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481120724?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:22","pubTimestamp":1731064920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 06:22 ET (11:22 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2482253816","title":"Vor Biopharma GAAP EPS of -$0.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2482253816","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482253816?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:21","pubTimestamp":1731064914,"startTime":"0","endTime":"0","summary":"Vor Biopharma press release (NASDAQ:VOR): Q3 GAAP EPS of -$0.40.\nCash, cash equivalents and marketable securities were $62.8 million as of September 30, 2024, which is projected to fund operations into the second half of 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4264825-vor-biopharma-gaap-eps-of-0_40","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["VOR"],"gpt_icon":0},{"id":"2481612540","title":"Barclays Keeps Their Buy Rating on Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481612540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481612540?lang=en_us&edition=fundamental","pubTime":"2024-11-08 17:51","pubTimestamp":1731059481,"startTime":"0","endTime":"0","summary":"Barclays analyst Carter Gould maintained a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $3.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-vor-biopharma-vor-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-vor-biopharma-vor-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR"],"gpt_icon":0},{"id":"2481119283","title":"Vor Biopharma Inc : Baird Cuts Target Price to $14 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2481119283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481119283?lang=en_us&edition=fundamental","pubTime":"2024-11-08 14:13","pubTimestamp":1731046436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3MF07L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2481119836","title":"Vor Biopharma Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481119836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481119836?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:57","pubTimestamp":1731045479,"startTime":"0","endTime":"0","summary":"Vor Biopharma, Inc. ( ($VOR) ) has released its Q3 earnings. Here is a breakdown of the information Vor Biopharma, Inc. presented to its investors....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2481116482","title":"Vor Biopharma Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481116482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481116482?lang=en_us&edition=fundamental","pubTime":"2024-11-08 10:25","pubTimestamp":1731032758,"startTime":"0","endTime":"0","summary":"Vor Biopharma Inc reports results for the quarter ended in September 30 - Earnings Summary  Vor Biopharma Inc VOR.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ended Sept","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2481316362","title":"Vor Biopharma Q3 EPS $(0.40), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2481316362","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481316362?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:37","pubTimestamp":1731019050,"startTime":"0","endTime":"0","summary":"Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 18.37 percent increase over losses of $(0.49) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41828999/vor-biopharma-q3-eps-0-40-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vor Biopharma Q3 EPS $(0.40), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2481163279","title":"Vor Biopharma Inc  Q3 Shr View $-0.40 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2481163279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481163279?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABWSHZS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2481197020","title":"Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481197020","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481197020?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology  2024 annual meeting. Han Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer. CAMBRIDGE, Mass., Nov. 07, 2024  -- Vor Bio , a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update.“We are pleased with our operational and clinical execution this quarter and look forward to sharing additional clinical data since our September data update at the ASH annual meeting in December,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer.25 patients have been dosed with trem-cel and 6 patients have now received the third dose level of Mylotarg at 2 mg/m2.On September 5, 2024, the Company provided a clinical update on 18 patients treated with trem-cel in the VBP101 study. The data demonstrated:. VBP301, a Phase 1/2, multicenter,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-reports-third-quarter-210500598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASH","ADC","BK4109","BK4080","BK4231","BK4139","VOR","LU2463526074.USD"],"gpt_icon":0},{"id":"2480884808","title":"Vor Biopharma Inc    expected to post a loss of 40 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480884808","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480884808?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:06","pubTimestamp":1730470016,"startTime":"0","endTime":"0","summary":"* Vor Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst estim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vor Biopharma Inc    expected to post a loss of 40 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2475528776","title":"Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2475528776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475528776?lang=en_us&edition=fundamental","pubTime":"2024-10-15 17:02","pubTimestamp":1728982939,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Indivior (GB:INDV – Research Report), Vor Biopharma ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-indivior-gbindv-vor-biopharma-vor-and-allogene-therapeutics-allo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-indivior-gbindv-vor-biopharma-vor-and-allogene-therapeutics-allo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","VOR","INDV","BK4139","BK4227","HCSG","BK4007","BK4106","ALLO","GB","BK4137"],"gpt_icon":0},{"id":"2471803445","title":"Vor Biopharma Names Han Choi as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2471803445","media":"MT Newswires Live","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471803445?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:09","pubTimestamp":1727694589,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR) said Monday that Han Choi was named as its chief financial officer, effective immediately.Choi previously served as a principal at Oracle Investment Management, a hedge fund focused on healthcare investments, said Vor Biopharma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348723411.USD","LU1366333091.USD","IE00BMPRXR70.SGD","LU0208291251.USD","LU0980610538.SGD","IE0004445239.USD","BK4581","LU1037948541.HKD","LU0130102774.USD","LU0417517546.SGD","BK4516","LU0965509010.AUD","BK4585","IE0002270589.USD","LU0719512351.SGD","LU1506573853.SGD","VOR","BK4538","LU0082616367.USD","LU1489326972.SGD","LU0949170772.SGD","LU0068578508.USD","LU0861579265.USD","BK4534","IE00B7SZLL34.SGD","LU0175139822.USD","LU0198837287.USD","IE00BBT3K403.USD","LU0965509101.SGD","LU1069347547.HKD","LU1934455277.USD","BK4139","LU0056508442.USD","IE00BMPRXN33.USD","BK4097","LU0289960550.SGD","LU0433182093.SGD","IE00B19Z3581.USD","LU1435385759.SGD","LU1429558221.USD","BK4528","IE00BN8TJ469.HKD","LU1803068979.SGD","LU0985489474.SGD","LU0738911758.USD","LU0965508806.USD","LU0323591593.USD","LU1934455194.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2471808020","title":"Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.d., LL.m., as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2471808020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471808020?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:00","pubTimestamp":1727694000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nTUAC6DSZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2466454770","title":"Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466454770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466454770?lang=en_us&edition=fundamental","pubTime":"2024-09-10 22:40","pubTimestamp":1725979212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAB Biotherapeutics (SABS – Research Report) and Vor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sab-biotherapeutics-sabs-and-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-sab-biotherapeutics-sabs-and-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","HCSG","SABS","VOR"],"gpt_icon":0},{"id":"2466498171","title":"Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2466498171","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466498171?lang=en_us&edition=fundamental","pubTime":"2024-09-10 22:20","pubTimestamp":1725978022,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vor/vor-biopharma/news/vor-biopharma-nasdaqvor-will-have-to-spend-its-cash-wisely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","LU2210149790.SGD","LU2095319765.USD",".IXIC","MNQmain","IE00BGHQF748.EUR","TQQQ","LU2210150020.SGD","IE00BKPKM429.USD","QLD","BK4139","NQmain","SQQQ","QID","IE00B64PRP62.GBP","VOR","NDAQ","BK4585","IE00B3QW5Z07.USD","BK4588","BK4112"],"gpt_icon":1},{"id":"2465269652","title":"Evercore ISI Keeps Their Buy Rating on Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465269652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465269652?lang=en_us&edition=fundamental","pubTime":"2024-09-06 20:06","pubTimestamp":1725624401,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat maintained a Buy rating on Vor Biopharma (VOR – Research Report) today. The company’s shares closed yesterday at $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":0.0453},{"period":"1month","weight":0.124},{"period":"3month","weight":-0.0823},{"period":"6month","weight":-0.4206},{"period":"1year","weight":-0.556},{"period":"ytd","weight":-0.6369}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.158438},{"month":2,"riseRate":0.666667,"avgChangeRate":0.051123},{"month":3,"riseRate":0.25,"avgChangeRate":-0.094474},{"month":4,"riseRate":0,"avgChangeRate":-0.211155},{"month":5,"riseRate":0.25,"avgChangeRate":-0.168862},{"month":6,"riseRate":0.25,"avgChangeRate":-0.134351},{"month":7,"riseRate":0,"avgChangeRate":-0.123744},{"month":8,"riseRate":0.5,"avgChangeRate":0.013788},{"month":9,"riseRate":0.25,"avgChangeRate":-0.127012},{"month":10,"riseRate":0.75,"avgChangeRate":0.068664},{"month":11,"riseRate":0.25,"avgChangeRate":-0.081592},{"month":12,"riseRate":1,"avgChangeRate":0.222933}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction